Portfolio Companies

Affini-T orchestrates the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.

Discovering & developing innovative therapies for disorders of the brain and nervous system.

Developing first-in-class CAR-macrophage platform for oncology and non-oncology applications.

Developing innovative medicines in immunology.

Harnessing the immune system for improved patient outcomes using a targeted approach.

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases.

Pioneering the most comprehensive multiomics platform for early cancer detection.

Exploring uncharted territories in immunomodulation comprising Butyrophilins & Gamma-delta T cells.

Developing targeted therapeutics for complex diseases using novel single cell analyses.

Gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery.

Discovering breakthrough gene editing systems for curing disease.

Developing therapeutics for rare cancers, including anaplastic astrocytoma.

Developing gene therapies for rare immunology disorders.

Developing therapeutics for rare dermatological disorders.

Targeting a range of fibrotic diseases, with a focus on fibrotic tissue-specific inhibition of integrins.

Gene-editing platform to overcome cancers, cure genetic diseases, and enable development of safer food.

Charting a course to therapeutics for difficult-to-treat cancers.

Small molecule platform company for alternative modulation of RNA.

Bringing best-in-class immune-based therapies to patients in need.